We reviewed recent scientific literature and clinical guidelines to summarize the clinical utility of genetic testing for Retinitis Punctata Albescens (RPA) and Fundus Albipunctatus (FA), which are rare forms of inherited retinal dystrophies. Despite overlapping phenotypes, they differ in clinical progression and genetic etiology, with RLBP1 and RDH5 as primary causative genes. Molecular testing, including next-generation sequencing, whole exome and whole-genome sequencing, is widely available in accredited laboratories and enables accurate diagnosis. The prevalence of the condition remains largely unknown. Accurate differentiation between progressive and stationary forms is essential for appropriate clinical management and informed genetic counseling. Moreover, comprehensive genetic analysis may reveal unexpected findings, including carrier status for unrelated conditions or variants associated with other retinal disorders. These results underscore the importance of careful interpretation and counseling to support patient management and reduce the risk of disease transmission.